In November 2025, consumer research firm Circana estimated that households with at least one GLP-1 medication user already represented 23% of U.S. households, and projected that by 2030 they could account for up to 35% of all food and beverage units sold in the United States. For an industry that competed for decades on selling more volume to each consumer, that is a structural inversion of the value proposition. The question is no longer how to fill the cart fuller. It is how to make every bite a consumer with reduced appetite chooses to eat deliver more nutrition, more satiety, and more reason to come back.
This article reviews what is happening with GLP-1 medications globally and in Latin America, how they are actually changing food consumption, what major industry players are doing about it, and what all this means for the formulators and processors who supply the market. Every figure below is cited to its source and date; market projections are identified as such and distinguished from verified historical data.
1. The phenomenon in numbers — what GLP-1s are and how widely they are used
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of medications originally approved for the treatment of type 2 diabetes. They work by mimicking an intestinal hormone that regulates the insulin response, slows gastric emptying, and acts on the brain's appetite center to reduce hunger and increase satiety. In recent years, higher doses of the same active molecules have been approved for the treatment of obesity — opening a substantially larger market.
The molecules that dominate the category are semaglutide (marketed as Ozempic for diabetes and Wegovy for obesity, both by Novo Nordisk) and tirzepatide (Mounjaro for diabetes and Zepbound for obesity, both by Eli Lilly). Tirzepatide is technically a dual GLP-1/GIP agonist, with superior clinical efficacy in weight reduction.
On clinical outcomes, the reference trials established that at 68–72 weeks, semaglutide 2.4 mg produced average body weight reductions of approximately 14.9% (the STEP-1 trial), while tirzepatide 15 mg achieved 20.9% in SURMOUNT-1, with a significant fraction of participants exceeding 25% body weight reduction. Real-world data are somewhat more modest — a 2025 analysis of 6,477 actual users found an average reduction of 7.7% with semaglutide and 12.4% with tirzepatide at one year, in part reflecting partial adherence and doses below the maximum therapeutic level. Even so, these are magnitudes of weight loss unprecedented for an outpatient pharmacological intervention.
Real-world adoption has been rapid. According to KFF (Kaiser Family Foundation) polling from late 2025, approximately 12% of U.S. adults — roughly one in eight — reported currently taking a GLP-1, and 18% reported having taken one at some point. Gallup, in polling conducted in mid-2026, found that 11% of U.S. adults were using a GLP-1 specifically for weight loss, versus only 3% two years earlier. Penetration is highest in the 50-to-64 age bracket, where it reaches 22%.
The financial impact on pharmaceutical companies is massive. Eli Lilly reported in its Q4 2025 results full-year revenues of USD 65.2 billion for 2025, a 45% increase over 2024, driven almost entirely by Mounjaro (USD 22.97 billion, +99% year-over-year) and Zepbound (USD 13.54 billion, +175%). In Q3 2025, the tirzepatide franchise crossed USD 10 billion in a single quarter, overtaking Merck's Keytruda to become the world's best-selling drug. Novo Nordisk reported for 2025, in its SEC filing, sales of DKK 127 billion for Ozempic and DKK 79 billion for Wegovy — together on the order of USD 30 billion — though with growth decelerating due to competition from tirzepatide and compounded versions.
Market projections vary by analyst, but they converge on transformational scale. Morgan Stanley projected in 2026 that the global market for obesity and type 2 diabetes treatments could reach USD 190 billion by 2035, more than double 2025 levels. Goldman Sachs, more conservative, projected in 2026 a global anti-obesity drug market of USD 114 billion by 2030, though revising its previous estimates upward on the coming entry of oral GLP-1s. These are projections — not outcomes — but even conservative scenarios imply a consumer category structurally different from the one that existed in 2020.
2. How consumption actually changes — hard data from three years
The operational question for any food processor is not how much pharma companies are selling. It is what a consumer on GLP-1 treatment eats, does not eat, and buys. The empirical answer has been maturing since 2024 and is now reasonably consistent across multiple sources.
Total caloric reduction. A Morgan Stanley survey of active users reported 20% to 30% fewer daily calories. Circana, in its November 2025 report based on actual household purchase data, found that GLP-1 users consume approximately 21% fewer calories than their personal baselines. A study published in the journal Appetite in 2025 measured reductions of 720 to 990 calories per day among active users. A Danish study published in 2026 on 1,177 consumers documented, from actual supermarket receipts, that new GLP-1 users went from spending approximately DKK 52,523 (~USD 8,373) on food annually before treatment to DKK 35,051 (~USD 5,589) after — a real spending reduction of approximately one-third.
Most affected categories. The impact is not uniform. Circana, in its January 2025 report, found that the categories with the largest spending declines during the first year of treatment were frozen, refrigerated, and general food and beverages. Salty snacks and confectionery showed smaller but consistent declines. An analysis published in Appetite and confirmed across multiple sources documented that the categories that fall disproportionately are ultra-processed foods, sweetened beverages, refined grains, and red meat. Fresh fruits, leafy vegetables, water, and lean protein were the only categories with net consumption increases.
Alcoholic beverages. This is one of the most consistent secondary effects. A study published in JAMA Psychiatry found that semaglutide reduced total alcohol consumption in adults with alcohol use disorder, without changing the number of drinking days but reducing quantity per episode. American Medical Association analyses reported that 45.3% of GLP-1 patients who consumed at least one alcoholic drink per week reported a reduction after starting treatment. The mechanism is plausible — GLP-1 receptors project to the brain's reward circuit, and reduced reinforcement extends from food to other substances.
Between-meal snacking. Multiple analysts agree that the largest share of caloric reduction comes from eliminating between-meal snacking, not from a proportional reduction across the three main meals. This is a critical implication: the traditional snack category — sweets, salty snacks, sweet baked goods — is the one most structurally exposed to the GLP-1 phenomenon.
Restaurants. The impact on foodservice is more nuanced than the industry initially feared. Circana data from November 2025 showed that after a year of treatment, restaurant spending by GLP-1 users actually increased slightly (+0.9% on average), with growth in casual dining (+4.1%) and marginal growth in quick-service (+0.6%). The sector read: GLP-1 users are not eating out less — they are ordering differently and less, with lower average check sizes, fewer appetizers and desserts, and less alcohol accompanying meals.
Willingness to pay more. This is perhaps the most commercially relevant finding. An ADM study cited by Circana found that 80% of GLP-1 consumers are willing to pay more for products offering additional functional benefits, and 67% said "GLP-1 friendly" attributes are important factors in their purchasing decisions. GLP-1 users buy less volume, but spend more per unit. This is exactly the opposite of the traditional mass-market consumption model.
3. Nutrient density — the new competitive axis
The technical term that unifies the industry response is nutrient density: how much protein, fiber, vitamins, minerals, and functionality can be packed per calorie, per bite, or per serving. This is not a new concept — but in two years it moved from being a niche differentiating attribute to being a minimum condition for competing in multiple categories.
The mechanism behind this is not just behavioral. It is also clinical. Clinical trials have documented that between 25% and 40% of total weight loss in GLP-1 patients corresponds to lean mass (mainly muscle), not fat. Though this range is consistent with what is expected in any rapid weight loss, it has generated enough clinical concern that emerging medical guidelines in 2025–2026 recommend daily protein intake of 1.2 to 1.6 grams per kilogram of body weight, distributed throughout the day with at least 20–30 grams per meal, alongside resistance training. A 2025 American Society for Nutrition advisory suggested as a practical reference 80 to 120 grams of protein daily for most adults in active weight loss.
For the food formulator, this is a mandate. A consumer with reduced appetite who knows they must consume 100 grams of protein per day cannot afford a 200-calorie main meal with 6 grams of protein. They need 25–30 grams of protein in that same portion. And because their gastric capacity is reduced, they also need that protein to be high quality — from sources with a complete essential amino acid profile, high digestibility, and ideally enriched in leucine, the amino acid that activates muscle protein synthesis.
Alongside protein, fiber emerges as the second pillar. Fiber prolongs post-meal satiety (a synergistic effect with the GLP-1 mechanism itself), helps mitigate the constipation that is a common GLP-1 side effect, and regulates the glycemic response. Industry data cited in 2025 indicated that 29% of U.S. adults consumed less than 20 grams of fiber per day — well below dietary guidelines — and that "fiber" mentions in new product launches had grown 28% year-over-year.
4. How major industry players are responding
The response of major food companies has evolved in three identifiable waves between 2024 and 2026.
Wave 1 — Dedicated launches (2024). Nestlé was the first major company to launch a line explicitly designed for GLP-1 users: Vital Pursuit, in May 2024, with portion-controlled frozen meals, high protein content (20+ grams), and added fiber. Nestlé positioned it as its first major U.S. brand launch in 30 years — a signal of strategic scale, not opportunistic experimentation.
Wave 2 — Relabeling and incremental reformulation (2025). Conagra became the first major CPG manufacturer to add a "GLP-1 Friendly" front-of-pack seal to 26 frozen meals in its Healthy Choice line in early 2025. The strategy was elegant in its efficiency — it required no product reformulation, only the application of the seal to existing products that already met protein, fiber, and portion criteria. U.S. regulation (USDA's FSIS) permitted the seal on the basis that the products also carried accurate protein and fiber declarations, though explicitly clarifying that no formal regulatory standard exists for the term "GLP-1 friendly."
Danone launched in August 2025 Oikos Fusion, a yogurt beverage line specifically formulated for GLP-1 users, with 23 grams of protein per bottle, added leucine and vitamin D to support muscle retention, and prioritizing whey protein over casein — a technical decision based on whey's higher leucine content.
Wave 3 — Structural portfolio reframing (2025–2026). Nestlé, in August 2026, said it is exploring products tailored to GLP-1 use, and industry coverage described its approach as a reframing around nutrient density: a shift from "consumers eat less" toward "consumers get more nutrition per bite." Danone announced in March 2026 a definitive agreement to acquire British complete-nutrition brand Huel, in a deal reported at around €1 billion, to extend its functional nutrition portfolio. In the ingredient ecosystem, Kerry noted at CAGNY 2026 that more than 60% of food and beverage activity now involves reformulation, and suppliers such as Ingredion, Novonesis, and ofi agree that protein, fiber, and nutrient density lead those agendas.
An analysis published in August 2026 summarized the strategic lesson with useful precision: protein is the only nutrient that consumers today are willing to pay a premium for, and it is therefore the only reformulation that can sustain a price increase. But it also warned that added protein alone is not a competitive moat — according to The Food Institute, 25% of new launches already carry a protein claim. Differentiation is moving toward high-quality protein, with appropriate amino acid profile, integrated into a system that also delivers fiber, functionality, and taste.
5. Latin America — the wave that is coming, and why it will land differently
The public conversation on GLP-1 has been dominated by the United States, but Latin America is not a passive observer. It is, according to converging projections from multiple analysts, the region with the highest percentage growth in the GLP-1 market over the next decade. Grand View Research projected in 2026 that Latin America would grow at a CAGR of approximately 14.6% — the highest among world regions — though from a smaller base.
The demand fundamentals are in place. Mexico has an adult obesity prevalence (BMI ≥30) of approximately 36.9% according to World Obesity Federation estimates, with ENSANUT 2023 data documenting 38.5% obesity and abdominal obesity prevalence reaching 81%. For Brazil, the World Obesity Federation projects that by 2044 approximately 48% of adults will have obesity, and 16.6 million residents already carry a diabetes diagnosis (IDF Diabetes Atlas 2024). These are markets with metabolic disease burden at or above U.S. levels.
Availability has been closing the gap. Novo Nordisk launched semaglutide 2.4 mg (Wegovy) in Mexico in April 2025, and semaglutide is available as Ozempic in most Latin American markets via private prescription. Regionally, semaglutide captured approximately 51% of the Latin American GLP-1 market in 2025, and Brazil accounted for nearly 60% of regional revenue, with gradual expansion of public coverage through the SUS. Tirzepatide is being rolled out with faster projected growth — Mordor Intelligence projects a 12.1% CAGR for the molecule in the region through 2031.
But three structural differences from the U.S. market matter for any food-innovation strategy targeting the region:
- Coverage is predominantly private. Unlike the United States, where the debate centers on Medicare and private insurance coverage, in most Latin American markets access to GLP-1 is mainly out-of-pocket or via private health plans. This skews penetration toward higher-income segments — the same segment that buys premium products through modern retail channels.
- Prices are substantially different. In Mexico, Ozempic list prices are approximately 3,500–6,500 Mexican pesos per pen (~USD 180–340) depending on pharmacy and presentation, versus several hundred dollars in the United States without coverage. Even so, the monthly cost is out of reach for most households — reinforcing that the Latin American GLP-1 user in 2025–2026 is predominantly urban, upper-middle-class, and with access to private healthcare.
- Different food culture. The snacking-reduction pattern documented in the United States applies in a nuanced way in markets where three structured main meals remain the norm and where the snack industry has lower per-capita penetration. By contrast, adjustments in categories such as sweetened beverages (where several Latin American markets have some of the highest per-capita consumption in the world) and in processed meats have high potential for impact.
A Kerry study of Brazilian consumers found that approximately 70% of respondents were already aware of GLP-1 medications, and a significant fraction reported interest in considering them within the next 12 months. Awareness is in place well before real penetration — suggesting that the behavioral effect on food preferences could precede the pharmacological adoption itself, to the extent that consumers in LATAM regions adopt "GLP-1 inspired" patterns (high protein, high fiber, controlled portion) without necessarily being on treatment.
6. Implications for food processors and their suppliers
Synthesizing the accumulated evidence, there are five work vectors that any serious food processor should be evaluating or executing over the 2026–2028 horizon, adapted by category and market:
1. Protein density as a design parameter, not label decoration. Products competing today in functional beverages, dairy, snacks, and prepared meals categories are moving toward protein contents of 15–30 grams per serving as a floor, not a ceiling. This has direct sourcing implications — whey proteins (WPC 80, WPI), calcium caseinate, soy isolates, and alternative proteins like pea and rice are under simultaneous demand pressure. The availability, quality, and price of these ingredients are critical commercial variables for 2026–2027.
2. Functional fibers as a systemic component. Soluble fibers (inulin, oligofructose, resistant dextrin, beta-glucan) and insoluble fibers with neutral sensory profiles are becoming part of the standard reformulation toolkit, not niche ingredients. Their selection must be validated by matrix — not all fibers behave the same way in RTD beverages, in drinkable yogurt, or in protein bars.
3. Sugar reduction without compromising sensory profile. Both the GLP-1 consumer and the "GLP-1 inspired" consumer avoid added sugars, but sucrose reduction in a beverage or a yogurt cannot sacrifice mouthfeel or sweet balance. Hybrid systems combining stevia, monk fruit, and body-adding fibers are increasingly the norm. (Innova has documented this topic in detail in a separate journal article.)
4. Portability and adapted format. A consumer with reduced gastric capacity does not consume a traditional full meal. They consume mini-portions, sachets, drinkable shakes, and functional snacks that deliver 200–400 kcal with maximum nutrient density. The formats that work are the ones that fit in a bag, not on a family plate.
5. Technical documentation that withstands scrutiny. The GLP-1 consumer is more informed than the average and asks technical questions. Certificates of analysis with amino acid profile, digestibility (PDCAAS or DIAAS), real soluble-versus-insoluble fiber content, and absence of objectionable additives are not "nice to have" — they are part of the commercial proposition. Transparency becomes a condition of access to the premium channels where these products are sold at prices that support higher formulation costs.
7. Caveats and nuances — what the evidence does not yet resolve
Intellectual honesty requires naming what we still do not know. Three caveats:
Persistence of the effect after discontinuation. The STEP-4 and SURMOUNT-4 trials documented that patients regain approximately two-thirds of lost weight within one year of discontinuing treatment. In real-world practice, a 2025 analysis of thousands of patients found that only about half remained on treatment after one year, and KFF lists cost and side effects among the main reasons for stopping. This suggests that the behavioral effect on food demand may be more cyclical than structural for a significant fraction of the population — with implications for the stability of "GLP-1 friendly" product demand over time.
Difference between survey data and purchase data. Many of the figures cited by analysts come from self-reported surveys. Studies using objective purchase data (supermarket receipts, scanner data) tend to show more modest changes than survey-based reports. The truth is probably somewhere in between, and the directional bias is toward overestimating the magnitude of change.
The competitive horizon is moving. Oral GLP-1s have begun to arrive: Novo Nordisk launched the Wegovy pill, and Lilly's orforglipron was in regulatory review in early 2026. If they consolidate with a reasonable efficacy profile and significantly lower prices, global penetration — and particularly in markets like Latin America — could accelerate substantially. Alternatively, if long-term side effects not yet characterized appear (safety data beyond 5–7 years are limited), the adoption trajectory could be revised downward. Uncertainty is still material.
8. The bottom line — from selling more to being worth more
The GLP-1 phenomenon does not destroy food demand. It reconfigures it. It changes the economic unit from "how much is consumed" to "how much value is delivered per bite." It is, in that sense, the most powerful catalyst for a shift that was already underway but that the industry could defer — the move from a food industry designed for cheap volume to a food industry designed for nutrient density paid at a premium.
For the processor supplying supermarkets, restaurants, and foodservice chains in Latin America, the operational question is concrete: is your current portfolio designed for the consumer that is coming, or for the consumer that is leaving? The answer translates into sourcing decisions — which proteins, which fibers, which sweeteners, which antioxidant systems, which grades, which suppliers — that in 2026 are notably different from what they were in 2020.
Innova works with food processors across Latin America to adapt formulations and supply chains to this transition. The work is not swapping one ingredient for another. It is redesigning the system so that each portion — smaller, more valuable, more functional — delivers what the label promises and what the 2026-and-beyond consumer is actually looking for.
This article is offered for general informational purposes and does not constitute medical, regulatory, or commercial advice. Market estimates and projections cited are drawn from identified public sources (Novo Nordisk 2025 annual results filed with the SEC, Eli Lilly Q4 2025 earnings, Danone, KFF, Gallup, RAND, Circana, Morgan Stanley, Goldman Sachs, Kerry, Mordor Intelligence, peer-reviewed publications) and are valid as of publication date. Market data change rapidly and should be verified against primary sources at the time of any commercial decision. Formulation recommendations must be validated case by case with the specific process, packaging, and distribution conditions of each application.
